Yuki Noguchi
Yuki Noguchi is a correspondent on the Science Desk based out of NPR's headquarters in Washington, D.C. She started covering consumer health in the midst of the pandemic, reporting on mental health, vaccination, telehealth, and racial inequities in healthcare.
Noguchi started her career as a reporter, then an editor, for The Washington Post, primarily covering business and technology. Noguchi joined NPR as a business correspondent in 2008, just before the financial crisis and Great Recession. She has covered a wide range of issues, from the workplace to the earthquake and tsunami in her parents' native Japan in 2011. Her coverage of the impact of opioids on workers and their families won a 2019 Gracie Award as well as First Place and Best In Show in the radio category from the National Headliner Awards. Her work on medical debt, in partnership with Kaiser Health News, won a 2023 Gerald Loeb award and an award from the National Institutes of Health Care Management.
Noguchi grew up in St. Louis, likes to cook, has a degree in history from Yale and is raising two boys and two rescue dogs outside Washington DC.
-
Researchers have been chasing the dream of a cancer vaccine for decades. Some recent successes with mRNA technology are garnering excitement from patients, doctors, government and investors. -
Merck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend. Results are promising: The vaccine reduces recurrence and death alongside an immunotherapy drug.
-
A study of a personalized vaccine combined with an existing immunotherapy found the treatment helped patients with melanoma avoid cancer recurrence. The combination trains the patient's immune system to go after cancer cells.
-
Health advocates argue that lung cancer screening guidelines should expand beyond smoking history to factor in risks like family history and radon exposure.
